Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

SIMPLE SUMMARY: Renal medullary carcinoma (RMC) is a rare and highly aggressive renal cell carcinoma, with a median survival of 13 months. Platinum-based chemotherapy is the recommended standard of care for RMC, but no effective salvage regimens have been established to date. Previous comprehensive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Wiele, Andrew J., Surasi, Devaki Shilpa, Rao, Priya, Sircar, Kanishka, Su, Xiaoping, Bathala, Tharakeswara K., Shah, Amishi Y., Jonasch, Eric, Cataldo, Vince D., Genovese, Giannicola, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Msaouel, Pavlos
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124338/
https://ncbi.nlm.nih.gov/pubmed/33946504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13092170
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados